About HEALTHCAPS INDIA LIMITED Unlisted Shares
HEALTHCAPS INDIA LIMITED was incorporated on 06 December 1982. It is classified as a Non-govt company and is registered at Registrar of Companies, Chandigarh. Healthcaps India Limited is a WHO-GMP Certified Company and is in the production of Empty Hard Gelatin Capsule Shells (I.P. / B.P.). Healthcaps India Limited products are widely used in the encapsulation of drugs, vitamins, antibiotics, etc, whether in powder or in pellet form by major pharmaceutical companies in India and abroad. Healthcaps India Limited also manufactures BSE/TSE-free EHG Capsules using EDQM-approved gelatin. With the objective of creating an eco-friendly environment, with stringent quality control checks in place, the company chose the open spaces in Fatehpur, Punjab, 60 km from Chandigarh for its manufacturing facility. And to facilitate easy interaction with clients, it has established offices in Chandigarh, New Delhi, and Mumbai. The company's vision is to become a global leader in the manufacture of empty capsules, setting benchmarks in quality and regulatory systems, and creating new market spaces with a focus on innovation.
HEALTHCAPS INDIA INCORPORATION DETAILS
|
HEALTHCAPS INDIA CIN |
U74899PB1982PLC050929 |
|
HEALTHCAPS INDIA Registration Date |
06.12.1982 |
|
Category/Sub-category of the Company |
Public Company Limited by shares A company having share capital |
|
Address of the Registered office and contact details of Healthcaps India Limited |
Tehsil Balachaur, District -SBS Nagar (Nawanshahr), Punjab – 144522 Telephone: 01881-273637 |
|
Name, Address, and Contact Details of Registrar and Transfer Agent, if any |
M/s Beetal Financial & Computer Services Pvt Ltd Beetal House, 3rd Floor,99 Madangir, Behind Local Shopping Center, Near Data Harsukhdas Mandir New Delhi- 110062 |
PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY
|
Name and Description of main products/services |
% to the total turnover of the Company |
|
Manufacture and Sale of Empty Hard Gelatin and HPMC Capsules |
100% |
HEALTHCAPS INDIA BOARD OF DIRECTORS
Mr. Chiranjiv Singh (Managing Director)
Mrs. Hariti Singh (Whole Time Director)
Mr. I. S. Bindra (Director)
Mr. Gurucharan Singh (Independent Director)
Mr. ArunBhakoo (Independent Director)
PARTICULARS OF HEALTHCAPS INDIA SUBSIDIARY AND ASSOCIATE COMPANIES
HEALTHCAPS INDIA LIMITED does not have any subsidiary or associate company.
SHAREHOLDING PATTERN of HEALTHCAPS INDIA (As of 31-03-2020)
|
S. No. |
Shareholder’s Name |
Number of shares |
% of total Shares of the company |
|
1 |
Chiranjiv Singh (Promoter) |
26,50,468 |
65.65% |
|
2 |
Hariti Singh (Promoter) |
4,62,462 |
11.46% |
|
3 |
Public Shareholding |
9,24,260 |
22.89% |
|
|
Total |
40,37,190 |
100% |
INDUSTRY OUTLOOK
Indian Pharmaceutical market ranks as 3rd largest in the world in terms of volume and the 14th largest in terms of value. Healthcare has become one of the largest sectors of the Indian economy, in terms of both employment and revenue. India is known as the Pharmacy of the world and is the largest provider of generic drugs at a global level. The pharmaceutical industry of India supplies over 50% of the global demand for various vaccines, 40% of the generic demand in the USA, and 25% of all medicines in the United Kingdom. Excellent Research and development, low cost of labor, availability of management and technical personnel, and local equipment availability have helped India to manufacture pharma products at a very low cost.
The Indian healthcare market may see a 3 fold jump in terms of value to reach US$ 372 billion by FY 2022. The growth can be attributed to rising income, greater health awareness, increased precedence of lifestyle disease, and Indian prominence in making medicinal products for the treatment of COVID-19. India aims to achieve vaccination for COVID-19 of 30 Crore people in the next few months.
Export of pharmaceutical products from India stood at US$ 16.8 billion in FY 2020 and US$ 2.07 billion in the month of October 2020. In the first 3 quarters of FY 2021, India exported pharmaceuticals worth US$ 15.86 billion. India supplied around 45 tons and 400 million tablets of hydroxychloroquine to around 114 countries globally to treat COVID-19 patients in the initial stage of the COVID-19 pandemic. Exports in FY 2021 of Indian pharma products are expected to cross US$ 24 billion, increasing by over 16% when compared to FY 2020.
After the onset of COVID-19, the Indian pharmaceutical sector became the busiest sector in the Indian economy. The pandemic proved to be a boon in disguise for the Indian pharmaceutical sector.
PROFIT & LOSS STATEMENT OF HEALTHCAPS INDIA LIMITED (In Rs. Lakhs)
|
PARTICULARS |
2020 |
2019 |
2018 |
|
Revenue from Operations |
10,814.52 |
10,217.36 |
8,278.14 |
|
EBITDA |
1,868.31 |
2,101.49 |
950.15 |
|
EBITDA margins |
17.22% |
20.53% |
11.45% |
|
Finance Cost |
431.04 |
340.51 |
222.11 |
|
Depreciation |
357.13 |
328.43 |
277.41 |
|
Other Income |
35.01 |
16.34 |
21.17 |
|
Exceptional Items |
2.60 |
(12.26) |
(0.41) |
|
Profit Before Tax |
1,117.74 |
1,436.63 |
1,056.70 |
|
Total Tax |
291.89 |
428.11 |
394.46 |
|
Profit After Tax (PAT) |
825.85 |
1,008.52 |
662.24 |
|
PAT margin |
7.61% |
9.85% |
7.98% |
|
EPS (Rs.) |
20.46 |
24.98 |
16.40 |
BALANCE SHEET OF HEALTHCAPS INDIA LIMITED (In Rs. Lakhs)
|
PARTICULARS |
31st March 2020 |
31st March 2019 |
|
ASSETS |
||
|
NON CURRENT ASSETS |
||
|
Tangible assets |
7,578.53 |
6,764.13 |
|
Intangible assets |
1.89 |
1.03 |
|
Long-term Loans & Advances |
195.40 |
248.14 |
|
Other non-current assets |
14.40 |
1.69 |
|
TOTAL NON-CURRENT ASSETS |
7,790.22 |
7,014.98 |
|
CURRENT ASSETS |
||
|
Inventories |
2,214.93 |
1,725.03 |
|
Trade receivables |
4,121.15 |
3,954.81 |
|
Cash and cash equivalent |
297.48 |
276.71 |
|
Short-term Loans & Advances |
470.53 |
461.50 |
|
Other current assets |
14.96 |
15.33 |
|
TOTAL CURRENT ASSETS |
7,119.05 |
6,433.39 |
|
TOTAL ASSETS |
14,909.27 |
13,448.37 |
|
EQUITY AND LIABILITIES |
||
|
EQUITY |
||
|
Equity Share Capital |
403.72 |
403.72 |
|
Other Equity |
6,290.86 |
5,493.67 |
|
TOTAL EQUITY |
6,694.58 |
5,897.39 |
|
LIABILITIES |
||
|
NON CURRENT LIABILITIES |
||
|
Long term borrowings |
1,745.63 |
1,736.48 |
|
Provisions |
477.57 |
400.25 |
|
Tax liabilities |
846.28 |
796.30 |
|
TOTAL NON-CURRENT LIABILITIES |
3,069.48 |
2,933.03 |
|
CURRENT LIABILITIES |
||
|
Trade payables |
1,191.08 |
1,109.76 |
|
Short-term Borrowings |
2,106.94 |
1,905.39 |
|
Provisions |
238.28 |
309.59 |
|
Other current liabilities |
1,608.90 |
1,293.21 |
|
TOTAL CURRENT LIABILITIES |
5,145.21 |
4,617.95 |
|
TOTAL LIABILITIES |
8,214.69 |
7,550.99 |
|
TOTAL EQUITY AND LIABILITIES |
14,909.27 |
13,448.37 |
HEALTHCAPS INDIA DIVIDEND HISTORY
|
Particulars |
2020 |
2019 |
2018 |
|
Dividend (final + interim) (In Rs.) |
Nil |
Nil |
Nil |
PERFORMANCE OF THE HEALTHCAPS INDIA
Revenue from Operations of the company in FY 2020 was Rs. 10,814.52 Lakhs, as against Rs. 10,217.36 Lakhs in FY 2019. Revenue from Operations of the company increased by Rs. 597.16 Lakhs, which is about a 6% increase.
EBITDA of the company decreased by 11.10% from Rs. 2,101.49 Lakhs in FY 2019 to Rs. 1,868.31 Lakhs in FY 2020. EBITDA margins decreased from 20.53% in FY 2019 to 17.22% in FY 2020.
In FY 2019, the company incurred a profit of Rs. 1,008.52 Lakhs. In FY 2020 the company made a profit of Rs. 825.85 Lakhs, i.e. decrease of 18.11%
The Current Ratio of the company as of 31st March 2020 was 1.38.
The debt-to-equity ratio of the company as of 31st March 2020 was 0.57.
The book value per share of the company as of 31st March 2020 stood at Rs. 165.82.
